Neuraptive Therapeutics Reports Encouraging 24-Week Data for NTX-001 in NEUROFUSE Study
WAYNE, PA — Neuraptive Therapeutics, Inc. has unveiled compelling 24-week data from its ongoing NEUROFUSE study on NTX-001, bolstering the product’s status after the positive proof of concept results based …
Neuraptive Therapeutics Reports Encouraging 24-Week Data for NTX-001 in NEUROFUSE Study Read More